Background: The c-Met (Met) oncogene was originally isolated from a chemical carcinogen-treated human osteogenic sarcoma cell line by transfection analysis in NIH/3T3 cells. The Met proto-oncogene product was identified as a transmembrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. A high proportion of spontaneous NIH/3T3 transformants overexpress c-Met and by transfection analysis the c-Met proto-oncogene has been shown to exhibit transforming activity. Tyrosine phosphorylation of apparently normal Met protein has also been observed in certain human gastric carcinoma cell lines.
Description: Rabbit polyclonal to C-Met
Immunogen: KLH conjugated synthetic peptide derived from C-Met
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 155 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
